Research programme: antineoplastic antibodies - Monopar TherapeuticsAlternative Names: ATN-658; huATN-658; HuATN-658 - Monopar Therapeutics; Humanised ATN-658
Latest Information Update: 19 Sep 2016
At a glance
- Originator Attenuon LLC
- Developer Monopar Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Urokinase plasminogen activator receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours